The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Official Title: A Phase 1, Open-Label, Multicenter, Study of mRNA-2736 in Patients With Relapsed or Refractory Multiple Myeloma
Study ID: NCT05918250
Brief Summary: This study is designed to evaluate the safety and tolerability of mRNA-2736 in participants with RRMM.
Detailed Description: This open-label, Phase 1, dose-escalation, first-in-human (FIH) clinical study of mRNA-2736 in participants with RRMM is designed to evaluate the safety and tolerability of escalating doses of mRNA-2736, administered intravenously (IV), to determine maximum tolerated dose and/or recommended Phase 2 dose, pharmacokinetics, pharmacodynamics, and preliminary efficacy of mRNA-2736.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
UAB Hospital, Birmingham, Alabama, United States
University of Miami Health System, Miami, Florida, United States
Washington University Medical Center, Saint Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
The Mount Sinai Hospital, New York, New York, United States
Ohio State University Hospital, Columbus, Ohio, United States
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
UW Medical Center, Seattle, Washington, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada